Comparison of effectiveness between polaprezinc and Zinc acetate hydrate on hypozincemia in hemodialysis patients.

UMIN ID: UMIN000038759

Registered date:31/12/2019

Basic Information

• Recruitment status: Pending
• Health condition(s) or Problem(s) studied: Zinc deficiency
• Date of first enrollment: 2019/12/01
• Target sample size: 60
• Countries of recruitment: Japan
• Study type: Interventional

Intervention(s)

Zinc acetate hydrate(25mg/Tb) 1 tablet twice a day for 6 months.
Polaprezink(75mg/Tb) 1 tablet twice a day for 6 months.

Outcome(s)

• Primary Outcome: Efficacy and safety for 6 months from the start of administration.
• Secondary Outcome: copper deficiency

Key inclusion & exclusion criteria

• Age minimum: 40years-old
• Age maximum: 95years-old
• Gender: Male and Female
• Exclude criteria: Patient after enterectomy Patients with peritoneal dialysis Pregnant or breastfeeding Patients allergic to zinc acetate hydrate or polaprezinc Patients who are unable to carry out contraindications or contraception during the study period Patients who are difficult to take orally Patients with serum copper less than 30microg/dL Patients judged to be inappropriate for inclusion in the study by the principal investigator

Related Information

• Primary Sponsor: Kenwakai Hospital hemodialysis center
• Source(s) of Monetary Support: Kenwakai Hospital hemodialysis center